87 results
8-K
EX-10.1
ALLO
Allogene Therapeutics Inc
14 May 24
Other Events
4:40pm
standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes … set forth in the Underwriting Agreement.
4.15 Independent Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser hereunder
8-K
EX-1.1
ALLO
Allogene Therapeutics Inc
14 May 24
Other Events
4:40pm
agrees that it will not claim that the Underwriter has rendered advisory services of any nature or respect, or owes a fiduciary or similar duty
424B5
ALLO
Allogene Therapeutics Inc
14 May 24
Prospectus supplement for primary offering
4:38pm
supplement, the accompanying prospectus and the documents incorporated by reference herein that are not strictly historical in nature are forward-looking … and therein that are not strictly historical in nature are forward-looking statements within the meaning of Section 27A of the Securities Act
8-K
EX-99.1
ALLO
Allogene Therapeutics Inc
13 May 24
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
4:02pm
; the limited nature of the Phase 1 data from our clinical trials and the extent to which such data may or may not be validated in any future clinical
S-3
EX-4.6
6i0w1gl5h7om zn1n
14 Mar 24
Shelf registration
5:21pm
S-3
0tiwl
14 Mar 24
Shelf registration
5:21pm
POSASR
d8dee76p byxe
14 Mar 24
Automatic shelf registration (post-effective amendment)
4:51pm
8-K
EX-99.1
vqknbq4ygn xmj
14 Mar 24
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023
4:10pm
8-K
wu644ehb0hpeaf9pfh0b
16 Feb 24
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
8:30am
8-K
za0pl 77v
5 Jan 24
Entry into a Material Definitive Agreement
8:00am
424B5
s625d
2 Nov 23
Prospectus supplement for primary offering
4:41pm